Biohit Oyj - Changes board/management/auditors

Osmo Suovaniemi becomes Chairman of the Board of Directors of Biohit Oyj

The new Board of Directors of Biohit Oyj, elected in the Annual General Meeting
on April 13th 2011, has appointed Professor Osmo Suovaniemi (MD, PhD) Chairman
of the Board in its meeting on April 21st 2011. Professor Suovaniemi is founder
and former CEO of Biohit. 

As of April 13th 2011 other Board Members are: MSc (Eng.), MBA, Kalle Kettunen
(CEO of Telko Oy); Professor Mikko Salaspuro (University of Helsinki); MSc
(Soc. Sc.), Eero Lehti (Member of Parliament); BSc (Eng.), Petteri Kilpinen
(CEO of TBWA\Helsinki Oy); MSc (Eng.) Seppo Luode; and MSc (Eng.), Saila
Miettinen-Lähde (CFO of Talvivaara Mining Company Plc). 

Further information on Biohit Oyj's Board members can be found on
www.biohit.com/investors. 



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com

About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 420 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com